CytoMed Therapeutics Limited (GDTC)
$0.81-8.99%Close
BUYCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $10M
- Beta
- 0.05
- P/E (TTM)
- -2.59
- Short % float
- 0.49%
- Days to cover
- 1.1
- SI change
- +372.4%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 4
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-52.3%
REV YoY-
ROE-87.2%
EPS YoY-
ROA-78.5%
GROSS-95
OP-853
NET-826
[VALUATION]
P/E TTM-2.59
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B2.84
P/FCF-
EV/EBITDA-2.14
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E9.13
ALTMAN Z-
CURR RATIO2.64
ND/EBITDA-
BETA0.05
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on GDTC?
- LOPJLB’s latest quantitative signal on CytoMed Therapeutics Limited (GDTC) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is GDTC in?
- CytoMed Therapeutics Limited (GDTC) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does CytoMed Therapeutics Limited (GDTC) do?
- CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR)…